Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F.

Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z. Review.

2.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators.

Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4.

PMID:
30201421
3.

Topographic staging of tau positron emission tomography images.

Schwarz AJ, Shcherbinin S, Slieker LJ, Risacher SL, Charil A, Irizarry MC, Fleisher AS, Southekal S, Joshi AD, Devous MD Sr, Miller BB, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2018 Feb 14;10:221-231. doi: 10.1016/j.dadm.2018.01.006. eCollection 2018.

4.

Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.

Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):413-21. doi: 10.1002/pds.3975. Epub 2016 Feb 17.

PMID:
26889887
5.

Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.

Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C.

Atherosclerosis. 2014 Aug;235(2):384-91. doi: 10.1016/j.atherosclerosis.2014.04.032. Epub 2014 May 22.

6.

Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine.

Gooden KM, Bibeau KB, Wood J, Irizarry MC, Pan X, Allen J, Sampson T, Heim JM.

Curr Drug Saf. 2015;10(2):152-8.

PMID:
24861991
7.

Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.

Davidson JE, Lockhart A, Amos L, Stirnadel-Farrant HA, Mooser V, Sollberger M, Regeniter A, Monsch AU, Irizarry MC.

Alzheimers Res Ther. 2012 Dec 7;4(6):51. doi: 10.1186/alzrt154. eCollection 2012.

8.

The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials.

Yaffe K, Tocco M, Petersen RC, Sigler C, Burns LC, Cornelius C, Khachaturian AS, Irizarry MC, Carrillo MC.

Alzheimers Dement. 2012 May;8(3):237-42. doi: 10.1016/j.jalz.2011.12.005.

PMID:
22546356
9.

Incidence of new-onset seizures in mild to moderate Alzheimer disease.

Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS.

Arch Neurol. 2012 Mar;69(3):368-72. doi: 10.1001/archneurol.2011.830.

10.

Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.

Irizarry MC, Webb DJ, Boudiaf N, Logie J, Habel LA, Udaltsova N, Friedman GD.

Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):214-25. doi: 10.1002/pds.2266. Epub 2011 Dec 6.

11.

Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.

Stirnadel HA, Bains C, Lakshmi M, Pandey R, Webb DJ, Irizarry MC, Hunt CM.

Regul Toxicol Pharmacol. 2012 Mar;62(2):329-35. doi: 10.1016/j.yrtph.2011.10.013. Epub 2011 Oct 28.

PMID:
22057095
12.

Modeling Alzheimer's disease progression using the disease system analysis approach.

Gomeni R, Simeoni M, Zvartau-Hind M, Irizarry MC, Austin D, Gold M.

Alzheimers Dement. 2012 Jan;8(1):39-50. doi: 10.1016/j.jalz.2010.12.012. Epub 2011 Jul 22.

PMID:
21782528
13.

Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsy.

Cunnington MC, Webb DJ, Irizarry MC, Manjunath R.

Epilepsy Behav. 2011 Jun;21(2):168-72. doi: 10.1016/j.yebeh.2011.03.017. Epub 2011 Apr 30.

PMID:
21531633
14.

Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan.

Koshy B, Miyashita A, St Jean P, Stirnadel H, Kaise T, Rubio JP, Mooser V, Kuwano R, Irizarry MC.

J Alzheimers Dis. 2010;21(3):775-80. doi: 10.3233/JAD-2010-100513.

PMID:
20634581
15.

Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.

Serrano-Pozo A, Vega GL, Lütjohann D, Locascio JJ, Tennis MK, Deng A, Atri A, Hyman BT, Irizarry MC, Growdon JH.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):220-6. doi: 10.1097/WAD.0b013e3181d61fea.

16.

Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.

Kachroo A, Irizarry MC, Schwarzschild MA.

Exp Neurol. 2010 Jun;223(2):657-61. doi: 10.1016/j.expneurol.2010.02.007. Epub 2010 Feb 24.

17.

An exploration of cognitive subgroups in Alzheimer's disease.

Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung GY, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, George-Hyslop PS, Wherrett J, Monsch AU.

J Int Neuropsychol Soc. 2010 Mar;16(2):233-43. doi: 10.1017/S1355617709991160. Epub 2009 Dec 4.

18.

Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials.

Irizarry MC, Webb DJ, Ali Z, Chizh BA, Gold M, Kinrade FJ, Meisner PD, Blum D, Silver MT, Weil JG.

Clin J Pain. 2009 Jul-Aug;25(6):469-76. doi: 10.1097/AJP.0b013e31819ddded.

PMID:
19542793
19.

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.

Dement Geriatr Cogn Disord. 2009;27(5):458-64. doi: 10.1159/000216841. Epub 2009 May 7.

PMID:
19420940
20.

Performance characteristics of plasma amyloid-beta 40 and 42 assays.

Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F.

J Alzheimers Dis. 2009;16(2):277-85. doi: 10.3233/JAD-2009-0948.

21.

Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial.

Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC.

Neurology. 2009 Jan 20;72(3):268-72. doi: 10.1212/01.wnl.0000339486.63862.db.

22.

Plasma urate and progression of mild cognitive impairment.

Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS.

Neurodegener Dis. 2009;6(1-2):23-8. doi: 10.1159/000170883. Epub 2008 Nov 5.

23.

Serum cystatin C and the risk of Alzheimer disease in elderly men.

Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry MC, Giedraitis V, Rönnemaa E, Degerman-Gunnarsson M, Hyman BT, Basun H, Kilander L, Lannfelt L.

Neurology. 2008 Sep 30;71(14):1072-9. doi: 10.1212/01.wnl.0000326894.40353.93.

24.

Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study.

Grodstein F, van Oijen M, Irizarry MC, Rosas HD, Hyman BT, Growdon JH, De Vivo I.

PLoS One. 2008 Feb 13;3(2):e1590. doi: 10.1371/journal.pone.0001590.

25.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
26.

Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC.

Arch Neurol. 2008 Jun;65(6):776-85. doi: 10.1001/archneur.65.6.776.

27.

Genotyping of apolipoprotein E: comparative evaluation of different protocols.

Ingelsson M, Shin Y, Irizarry MC, Hyman BT, Lilius L, Forsell C, Graff C.

Curr Protoc Hum Genet. 2003 Nov;Chapter 9:Unit9.14. doi: 10.1002/0471142905.hg0914s38.

PMID:
18428347
28.

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L.

Arch Neurol. 2008 Feb;65(2):256-63. doi: 10.1001/archneurol.2007.57.

PMID:
18268197
29.

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.

Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD.

Arch Neurol. 2008 Jan;65(1):45-53. Epub 2007 Nov 12.

PMID:
17998437
30.

The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.

Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L.

Neurosci Lett. 2007 Nov 12;427(3):127-31. Epub 2007 Sep 20.

PMID:
17936506
31.

Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease.

Irizarry MC, Yao Y, Hyman BT, Growdon JH, Praticò D.

Neurodegener Dis. 2007;4(6):403-5. Epub 2007 Oct 9.

PMID:
17934322
32.

Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.

Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S, Matsui T, Growdon JH, Frosch MP, Ghetti B, Brown RH, Irizarry MC, Hyman BT.

Acta Neuropathol. 2007 Nov;114(5):471-9. Epub 2007 Aug 25.

PMID:
17721707
33.

Expression of APP pathway mRNAs and proteins in Alzheimer's disease.

Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, Irizarry MC, Hyman BT.

Brain Res. 2007 Aug 3;1161:116-23. Epub 2007 Jun 5.

PMID:
17586478
34.

Plasma Abeta levels do not reflect brain Abeta levels.

Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC.

J Neuropathol Exp Neurol. 2007 Apr;66(4):264-71.

PMID:
17413317
35.

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.

Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH.

Arch Neurol. 2007 Mar;64(3):431-4.

PMID:
17353389
36.

Prospective study of plasma folate, vitamin B12, and cognitive function and decline.

Kang JH, Irizarry MC, Grodstein F.

Epidemiology. 2006 Nov;17(6):650-7.

PMID:
17028506
37.

GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing.

von Arnim CA, Spoelgen R, Peltan ID, Deng M, Courchesne S, Koker M, Matsui T, Kowa H, Lichtenthaler SF, Irizarry MC, Hyman BT.

J Neurosci. 2006 Sep 27;26(39):9913-22.

38.

Prevalence and effects of lobar microhemorrhages in early-stage dementia.

Atri A, Locascio JJ, Lin JM, Yap L, Dickerson BC, Grodstein F, Irizarry MC, Growdon JH, Greenberg SM.

Neurodegener Dis. 2005;2(6):305-12.

PMID:
16909013
39.

No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain.

Ingelsson M, Ramasamy K, Cantuti-Castelvetri I, Skoglund L, Matsui T, Orne J, Kowa H, Raju S, Vanderburg CR, Augustinack JC, de Silva R, Lees AJ, Lannfelt L, Growdon JH, Frosch MP, Standaert DG, Irizarry MC, Hyman BT.

Acta Neuropathol. 2006 Oct;112(4):439-49. Epub 2006 Jun 27.

PMID:
16802167
40.

Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels.

Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT.

J Neuropathol Exp Neurol. 2006 May;65(5):508-15.

PMID:
16772874
41.

Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.

Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT.

Acta Neuropathol. 2006 Feb;111(2):101-8. Epub 2006 Feb 16.

PMID:
16482476
42.

Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease.

Holtzer R, Irizarry MC, Sanders J, Hyman BT, Wegesin DJ, Riba A, Brandt J, Albert M, Stern Y.

Arch Neurol. 2006 Feb;63(2):226-30.

PMID:
16476811
43.

Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.

Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT.

J Neurosci. 2006 Jan 11;26(2):418-28.

44.

Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM.

Neurology. 2006 Jan 10;66(1):23-9.

PMID:
16401840
45.

Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.

Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T.

Neurology. 2005 Nov 8;65(9):1402-8.

PMID:
16275827
46.

Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.

Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT, Ingelsson M.

Exp Neurol. 2005 Jul;194(1):91-6.

PMID:
15899246
47.

The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.

von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT.

J Biol Chem. 2005 May 6;280(18):17777-85. Epub 2005 Mar 4.

48.

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.

Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE.

J Biol Chem. 2005 Apr 29;280(17):17458-63. Epub 2005 Feb 21.

49.

Biomarkers of Alzheimer disease in plasma.

Irizarry MC.

NeuroRx. 2004 Apr;1(2):226-34. Review.

50.

Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy.

von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, Hyman BT.

J Cell Sci. 2004 Oct 15;117(Pt 22):5437-45. Epub 2004 Oct 5.

Supplemental Content

Loading ...
Support Center